A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd